On July 11, encouraging news came from the ETER701 study completed by 72 centers nationwide led by Professor Cheng Ying of Jilin Cancer Hospital. The academic paper Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial was published online in the international authoritative medical journal Nature ETER701 was a study of Chiatai Tianqing's Benmelstobart and anlotinib in combination with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. The study showed that the median progression-free survival (mPFS) and median overall survival (mOS) of patients included in the current study were the highest in the history of the registry study, and that the combination chemotherapy regimen of Benmelstobart and amlotinib is expected to provide a survival benefit for patients with extensive-stage small cell lung cancer (ES-SCLC).

This is another authoritative recognition of Benmelstobart in combination with amlotinib and chemotherapy in the field of extensive-stage small cell lung cancer, following the first publication of the data at the World Conference on Lung Cancer (WCLC) 2023. Previously, the 2024 CSCO Guidelines for the Treatment of Small Cell Lung Cancer highlighted this therapy in the Notes section for first-line treatment of extensive-stage small cell lung cancer.

The ETER701 study was a multicenter, placebo-controlled, randomized Phase III clinical trial. A total of 738 patients were enrolled in this study, of which 246 patients were assigned to the Benmelstobart +lotinib + chemotherapy arm and 247 patients were assigned to the placebo + chemotherapy arm. The data cut-off date was May 14, 2022, with a median follow-up of 14.0 months.

Among the primary endpoints, there was a significant difference in median PFS assessed by IRC between the two populations, 6.93 months vs. 4.21 months, respectively; there was also a more significant difference in median OS, 19.32 months vs. 11.89 months, respectively. This study suggests that in the first-line treatment of ES-SCLC, the addition of anti-angiogenic drugs to immuno-combination chemotherapy resulted in the highest median PFS and median OS in the history of the registry study, and the results of the study support that the use of immuno-combination of anti-angiogenic drugs and chemotherapy, a four-drug paradigm, could be a new option for the first-line treatment of patients with ES-SCLC.

The ETER701 study not only provides a new treatment strategy for patients with extensive-stage small cell lung cancer, but also marks an important step in the combined application of immune-combined anti-angiogenic drugs and chemotherapy, injecting new vitality into the global anti-tumor cause.

In the first half of this year, Chiatai Tianqing has received a lot of good news in the field of innovative drugs, and three Class 1 innovative drugs, namely Anektinib, Benmelstobart and Efenac, have been approved and listed on the market, which is the domestic pharmaceutical company with the most Class 1 innovative drugs approved in the first half of the year. Recently, at the T20 conference, Anlotinib was honored with the "China New Drug Pioneer Award", which is one of the top 20 innovative drugs in China in the past 20 years.

https://mp.weixin.qq.com/s?__biz=MzA5NDE4ODc2MA==&mid=2650367942&idx=2&sn=f8b3675bc545b804d85731ea3dad72ab&chksm=885fa271bf282b67550afc5aeb0c9074adb912673baab169383b03817129940954dc76a05390&mpshare=1&scene=1&srcid=0717w6OSLFQ05Xd9eWCWxx5H&sharer_shareinfo=eb85eaa4d5ee1747e2211a827eb4fb57&sharer_shareinfo_first=eb85eaa4d5ee1747e2211a827eb4fb57#rd